FDA's Improved Forensics Uncovers More Manufacturing Data Integrity Issues
Executive Summary
Agency learned how to find hidden information during its investigation of Ranbaxy, with techniques including improved forensic examinations of firm computers; mock inspections held at Indian and Chinese sites ahead of FDA visits.
You may also be interested in...
Novartis' Zolgensma Had Manipulated Data In Application, US FDA Says
Gene therapy should remain on the market, FDA says, but Novartis could face civil or criminal penalties. Firm knew of problems before approval.
Ranbaxy’s $500 Million Settlement Includes Criminal Penalties
The generic drug maker’s Ranbaxy USA Inc. subsidiary pleads guilty to seven felony counts brought in connection with a longstanding government investigation into data integrity issues and manufacturing violations at two Indian sites, but while the settlement eliminates some worries for the firm, operations still face the weight of a FDA consent decree.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.